<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[RSS Feed]]></title><description><![CDATA[RSS Feed]]></description><link>http://direct.ecency.com</link><image><url>http://direct.ecency.com/logo512.png</url><title>RSS Feed</title><link>http://direct.ecency.com</link></image><generator>RSS for Node</generator><lastBuildDate>Thu, 07 May 2026 20:42:01 GMT</lastBuildDate><atom:link href="http://direct.ecency.com/created/amarin/rss.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Amarin Vascepa]]></title><description><![CDATA[From Motley Fool: Campbell: Amarin markets a drug called Vascepa. Vascepa is a purified omega three fatty acid. We'll call it EPA. It's been on the market since 2012 for use in reducing triglycerides,]]></description><link>http://direct.ecency.com/amarin/@nextlcoin/amarin-vascepa</link><guid isPermaLink="true">http://direct.ecency.com/amarin/@nextlcoin/amarin-vascepa</guid><category><![CDATA[amarin]]></category><dc:creator><![CDATA[nextlcoin]]></dc:creator><pubDate>Tue, 02 Oct 2018 14:54:45 GMT</pubDate></item></channel></rss>